Lonza Announces New, Vascular Health Receptor Screened Human Umbilical Vein Endothelial Cells (HUVEC) as Innovative Extension of >2.5M CHF Primary Endothelial Cell Product Line

March 01,2012

Basel, Switzerland / Walkersville, Maryland, 01March 2012 – Lonza announces that it is expanding its human primary cell business to include endothelial cells pre-screened for the presence of four specific vascular health receptors. These cells will offer a more characterized version of the popular HUVEC for use in cancer, atherosclerosis, and heart disease research. The four receptors are VEGFr2, Axl, eNos, and Tie-2.

“Our HUVEC product line is very popular with our customers. Over the past few years, we have received numerous requests for more characterization pertaining to specific vascular cell health receptors. The new pre-screened HUVECs allow Lonza to better serve our customers and keep up with the advancing field of vascular research. We look forward to making this exciting new product available to our customers in early 2012.” explains Marjorie Smithhisler, Global Product Manager for Bioscience Research and Testing Solutions.

Lonza currently offers more than 30 different varieties of primary human endothelial cells including cells from normal, diabetic type I, and II donors, and from tissue sources ranging from heart to skin. Further information on these pre-screened HUVECs and other primary endothelial cells can be found at www.lonza.com/research.

Browse All News